**HRA Corporate Risk Register Overview – Quarter 1 2017/18**

**Impact**

**5**

|  |
| --- |
| **Key:****SIP risk** **Finance risk** **Social Care risk** **Systems risk** **Reputational risk** **Operational risk** **Risk increased since last quarter** **Risk decreased since last quarter** **HRA Controlled Risk****Risk Partially Controlled****Externally Controlled Risk****HRA Approval risk**  |

|  |  |  |
| --- | --- | --- |
|  |  |  |
| **Finance****559.** Unable to deliver strategic and statutory requirements due to spending review and external environment **NEW****562.** Unable to deliver strategically important change projects due to insufficient resources **NEW****HRA Approval****508.** Researchers perceive different HRA functions to be disjointed**553.** Stakeholders misunderstand / misinterpret predicted end to end timelines for studies **NEW** **SIP 548:** UK wide compatibility affected by SIP**Systems risk****521:** Lack of clarity re IRAS and HARP developments to align with EU Clinical Trial Portal in time  | **Transparency / reputation****004:** HRA unable to deliver level of expectation within its role to promote transparency **RE-RAISED****Systems risk****522:** Operational process changes and IT Changes following SIP do not align as quick as required **Social Care 288:** Unknown scope and expectations  |  |
|  | **HRA Approval****500.** Applicants not following HRA Approval Process  |  |

**4**

|  |
| --- |
| **Removed risks:****HRA Approval****375.** Acceptance varies due to ongoing information governance work **SIP 537:** Insufficient resources to deliver SIP and maintain BAU **523:** Operational process changes and IT Changes for UK wide programme of work do not align as quick as required**520:** Lack of clarity re technical developments**Reputational risk****377.** Stakeholders not receiving / understanding info  |
| **Closed risks:****HRA Approval****204.** Substantial change for stakeholders**206.** Identification of metrics **486.** NHS organisations may perceive timelines will be longer and show fall in performance  **Systems risk****547:** Essential Delivery Plan not fully undertaken affecting developments to IRAS |

**Likelihood**

**5**

**4**

**3**

**3**

**3**

**Likelihood**

**5**

**4**

**Trend analysis**

* A total of ten risks have been escalated to the corporate risk register for quarter 1.
* Three new risks have been added whilst one ‘older’ risk has been re-raised. Five risks have been removed since the last quarter with a further four having closed.
* Regarding the three new risks:
	+ Two risks relate to finance and the pressure on the HRA to deliver its strategic programmes of work and also statutory requirements due to lack of resources, both monetary and personnel, and also the impact of the spending review and the external environment.
	+ The other new risks relates to HRA Approval and people misunderstanding or misinterpreting the predicted end to end timelines for studies.
* The risk which has been re-raised relates to transparency. This has been escalated again as the risk of not implementing the new EU Clinical Trial Regs, as a result of Brexit, and not having access to the EU portal or the EMA may result in loss of transparency of CTIMPs.
* Of the closed risks, these largely relate to HRA Approval as stakeholders become more used to the process.
* Regarding the removed risks:
	+ One relates to SIP, and whilst the risk to delivery of SIP and BAU remains the LT agreed there are appropriate mitigations in place and the Board will receive regular updates on SIP as part of its governance role.
* A number of risks which have decreased relate to UK wide working with good relationships and process in place.